Novel Toxoplasma Gondii Inhibitor Chemotypes

Overview

Journal Parasitol Int

Publisher Elsevier

Specialty Parasitology

Date 2017 Oct 31

PMID 29081387

Citations 10

Authors

A G Sanford

T T Schulze

L P Potluri

R M Hemsley

J J Larson

A K Judge

S J Zach

X Wang

S A Charman

J L Vennerstrom

P H Davis

Affiliations

Soon will be listed here.

Abstract

We profiled three novel T. gondii inhibitors identified from an antimalarial phenotypic high throughput screen (HTS) campaign: styryl 4-oxo-1,3-benzoxazin-4-one KG3, tetrahydrobenzo[b]pyran KG7, and benzoquinone hydrazone KG8. These compounds inhibit T. gondii in vitro with IC values ranging from 0.3 to 2μM, comparable to that of 0.25 to 1.5μM for the control drug pyrimethamine. KG3 had no measurable cytotoxicity against five mammalian cell lines, whereas KG7 and KG8 inhibited the growth of 2 of 5 cell lines with KG8 being the least selective for T. gondii. None of the compounds were mutagenic in an Ames assay. Experimental gLogD and calculated PSA values for the three compounds were well within the ranges predicted to be favorable for good ADME, even though each compound had relatively low aqueous solubility. All three compounds were metabolically unstable, especially KG3 and KG7. Multiple IP doses of 5mg/kg KG7 and KG8 increased survival in a T. gondii mouse model. Despite their liabilities, we suggest that these compounds are useful starting points for chemical prospecting, scaffold-hopping, and optimization.

Citing Articles

Antimalarial Dibenzannulated Medium-Ring Keto Lactams.

Ren R, Wang X, Leas D, Scheurer C, Hoevel S, Cal M ACS Infect Dis. 2023; 9(10):1964-1980.

PMID: 37695781 PMC: 10860121. DOI: 10.1021/acsinfecdis.3c00245.

Quercetin inhibits Toxoplasma gondii tachyzoite proliferation and acts synergically with azithromycin.

Abugri D, Wijerathne S, Sharma H, Ayariga J, Napier A, Robertson B Parasit Vectors. 2023; 16(1):261.

PMID: 37537675 PMC: 10401810. DOI: 10.1186/s13071-023-05849-3.

Anti-Toxoplasma gondii activity of Trametes versicolor (Turkey tail) mushroom extract.

Sharma H, Catrett J, Nwokeocha O, Boersma M, Miller M, Napier A Sci Rep. 2023; 13(1):8667.

PMID: 37248277 PMC: 10225767. DOI: 10.1038/s41598-023-35676-6.

Neurological and Neurobehavioral Disorders Associated with Infection in Humans.

Virus M, Ehrhorn E, Lui L, Davis P J Parasitol Res. 2021; 2021:6634807.

PMID: 34712493 PMC: 8548174. DOI: 10.1155/2021/6634807.

Analogs of Marinopyrrole A Show Enhancement to Observed Potency against Acute Toxoplasma gondii Infection.

Martens M, Liu Y, Sanford A, Wallick A, Warner R, Li R Antimicrob Agents Chemother. 2021; 66(1):e0079421.

PMID: 34662196 PMC: 8765230. DOI: 10.1128/AAC.00794-21.

References

Liao C, Park J, Bang J, Nicklaus M, Lee K . Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. ACS Med Chem Lett. 2010; 1(3):110-114. PMC: 2898210. DOI: 10.1021/ml100020e. View

Chandramohanadas R, Davis P, Beiting D, Harbut M, Darling C, Velmourougane G . Apicomplexan parasites co-opt host calpains to facilitate their escape from infected cells. Science. 2009; 324(5928):794-7. PMC: 3391539. DOI: 10.1126/science.1171085. View

Westphal M, Wolfstadter B, Plancher J, Gatfield J, Carreira E . Evaluation of tert-butyl isosteres: case studies of physicochemical and pharmacokinetic properties, efficacies, and activities. ChemMedChem. 2015; 10(3):461-9. DOI: 10.1002/cmdc.201402502. View

Barnes-Seeman D, Jain M, Bell L, Ferreira S, Cohen S, Chen X . Metabolically Stable tert-Butyl Replacement. ACS Med Chem Lett. 2014; 4(6):514-6. PMC: 4027455. DOI: 10.1021/ml400045j. View

Lovering F, Bikker J, Humblet C . Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem. 2009; 52(21):6752-6. DOI: 10.1021/jm901241e. View

Kamerkar S, Davis P . Toxoplasma on the brain: understanding host-pathogen interactions in chronic CNS infection. J Parasitol Res. 2012; 2012:589295. PMC: 3321570. DOI: 10.1155/2012/589295. View

Misra S, Ghatak S, Patil N, Dandawate P, Ambike V, Adsule S . Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013; 21(9):2551-9. PMC: 3895464. DOI: 10.1016/j.bmc.2013.02.033. View

JACOB S, ROSENBAUM E . The toxicology of dimethyl sulfoxide (DMSO). Headache. 1966; 6(3):127-36. DOI: 10.1111/j.1526-4610.1966.hed0603127.x. View

Lombardo F, Shalaeva M, Tupper K, Gao F . ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J Med Chem. 2001; 44(15):2490-7. DOI: 10.1021/jm0100990. View

10.

Imming P, Sinning C, Meyer A . Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006; 5(10):821-34. DOI: 10.1038/nrd2132. View

11.

Weiss L, Dubey J . Toxoplasmosis: A history of clinical observations. Int J Parasitol. 2009; 39(8):895-901. PMC: 2704023. DOI: 10.1016/j.ijpara.2009.02.004. View

12.

Valko K, Nunhuck S, Bevan C, Abraham M, Reynolds D . Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci. 2003; 92(11):2236-48. DOI: 10.1002/jps.10494. View

13.

Peixoto L, Chen F, Harb O, Davis P, Beiting D, Brownback C . Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe. 2010; 8(2):208-18. PMC: 2963626. DOI: 10.1016/j.chom.2010.07.004. View

14.

McFarland M, Zach S, Wang X, Potluri L, Neville A, Vennerstrom J . Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity. Antimicrob Agents Chemother. 2016; 60(12):7017-7034. PMC: 5118980. DOI: 10.1128/AAC.01176-16. View

15.

Flegr J, Prandota J, Sovickova M, Israili Z . Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014; 9(3):e90203. PMC: 3963851. DOI: 10.1371/journal.pone.0090203. View

16.

Cohn J, McMeeking A, Cohen W, Jacobs J, Holzman R . Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am J Med. 1989; 86(5):521-7. DOI: 10.1016/0002-9343(89)90378-1. View

17.

Eguchi T, Kanai S, Kakinuma K, Okazaki T, Mizoue K . Synthesis of NG-061 and its analogs, and their biological evaluation as an enhancer of nerve growth factor. Chem Pharm Bull (Tokyo). 2000; 48(10):1470-3. DOI: 10.1248/cpb.48.1470. View

18.

Meneceur P, Bouldouyre M, Aubert D, Villena I, Menotti J, Sauvage V . In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother. 2008; 52(4):1269-77. PMC: 2292506. DOI: 10.1128/AAC.01203-07. View

19.

Caujolle F, Caujolle D, Cros S, CALVET M . Limits of toxic and teratogenic tolerance of dimethyl sulfoxide. Ann N Y Acad Sci. 1967; 141(1):110-26. DOI: 10.1111/j.1749-6632.1967.tb34871.x. View

20.

Guiguemde W, Shelat A, Bouck D, Duffy S, Crowther G, Davis P . Chemical genetics of Plasmodium falciparum. Nature. 2010; 465(7296):311-5. PMC: 2874979. DOI: 10.1038/nature09099. View